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Cysteine cathepsins control hepatic NF-κB-dependent
inflammation via sirtuin-1 regulation
Álvaro de Mingo1, Estefanía de Gregorio1, Anna Moles2, Núria Tarrats1, Anna Tutusaus1, Anna Colell1, Jose C Fernandez-Checa1,3,
Albert Morales1 and Montserrat Marí*,1
Sirtuin-1 (SIRT1) regulates hepatic metabolism but its contribution to NF-κB-dependent inflammation has been overlooked.
Cysteine cathepsins (Cathepsin B or S, CTSB/S) execute specific functions in physiological processes, such as protein
degradation, having SIRT1 as a substrate. We investigated the roles of CTSB/S and SIRT1 in the regulation of hepatic inflammation
using primary parenchymal and non-parenchymal hepatic cell types and cell lines. In all cells analyzed, CTSB/S inhibition reduces
nuclear p65-NF-κB and κB-dependent gene expression after LPS or TNF through enhanced SIRT1 expression. Accordingly, SIRT1
silencing was sufficient to enhance inflammatory gene expression. Importantly, in a dietary mouse model of non-alcoholic
steatohepatitis, or in healthy and fibrotic mice after LPS challenge, cathepsins as well as NF-κB-dependent gene expression are
activated. Consistent with the prominent role of cathepsin/SIRT1, cysteine cathepsin inhibition limits NF-κB-dependent hepatic
inflammation through the regulation of SIRT1 in all in vivo settings, providing a novel anti-inflammatory therapeutic target in liver
disease.
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Hepatic inflammation is a central part of the liver response to
injury elicited by diverse harmful stimuli such as alcohol,
cholestasis, and excess fat, among others.1 The essential
function of the liver for homeostasis and inflammatory
responses is emphasized by its anatomical location, allowing
continuous blood flow from the gastrointestinal tract through
the hepatic sinusoids. This allows hepatocytes and non-
parenchymal cells to interact with gut-derived pathogens and
their products, such as LPS.1 In this interplay, the regulation of
hepatic functions is greatly facilitated by cytokines, and both
LPS and the LPS-induced cytokine TNF play a central role in
liver homeostasis and inflammation through the activation of
NF-κB transcription factor in different liver cell populations.
NF-κB is a homo- or heterodimeric complex formed by Rel-like
domain-containing proteins, the p65-p50 complex being the
most abundant.
The activation of NF-κB leads to the transcription of genes
with “healthy” or “unhealthy” function depending on the cell
type,2 encoding for cytokines, chemokines, and also genes
coding for regulators of apoptosis and cell proliferation.3 Since
unrestrained inflammation may be harmful, NF-κB is regulated
at several levels, including controlled cytoplasmic-nuclear
shuttling and modulation of its transcriptional activity.3 In
unstimulated cells, NF-κB is held in the cytoplasm complexed
to its repressor IκB. In a conventional, or canonical, activation
pathway, NF-κB needs first to be freed from IκB. To this aim,
IκB is phosphorylated by IκB kinases in response to activators
such as LPS or TNF, and subsequently degraded, thus
liberating the active NF-κB complex, which translocates to
the nucleus. The post-translational regulation of the active
NF-κB subunits is mainly achieved by phosphorylation and
acetylation of p65 at specific residues2 that can either
enhance NF-κB activity, by controlling p65 recruitment binding
to κB DNA binding sites, or ending gene transcription by
inducing its nuclear export.4 The responsible enzymes for
these modifications are emerging but are not well
understood.2
Sirtuin-1 (SIRT1), a prototype mammalian NAD(+)-depen-
dent protein deacetylase, has emerged as a key metabolic
sensor in various metabolic tissues. Hepatic SIRT1 controls
several transcription factors that regulate glucose, lipid, and
cholesterol homeostasis.5 Actually, liver-specific SIRT1
knockout mice develop hepatic steatosis,6 and extensive
weight loss in obese patients increases sirtuin expression
significantly in both adipose tissue and liver, probably as a
consequence of reduced inflammation.7 Regarding
inflammation, it has been described that NF-κB is a target of
SIRT1. In their seminal study in 2004, Yeung et al.8
demonstrated that SIRT1 could directly deacetylate the p65
at lysine 310 residue, thus inhibiting the transactivation
capacity of p65 and suppressing NF-κB-dependent gene
transcription.
Cathepsin B (CTSB), a ubiquitous cysteine cathepsin, is a
lysosomal/endosomal protease whose participation in differ-
ent pathologies such as liver fibrosis,9 atherosclerosis,10
Alzheimer disease,11 and cancer12 has been reported in the
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past years. Moreover, CTSB has been implicated in hepatic
lysosomal disruption and apoptosis.13–15 Interestingly, CTSB
is also localized in the nucleus, where it is found to be
associated with the nuclear scaffold.16 Interestingly, the
proteolytic cleavage of SIRT1 by cysteine cathepsins, CTSB,
and Cathepsin S (CTSS), among others, has been observed
in osteoarthritic chondrocytes and endothelial progenitor
cells.17,18
Of note, in previous studies in murine models of toxic-
induced liver fibrosis, we observed that CTSB inhibition
mitigated chronic CCl4-induced inflammation, hepatic stellate
cell (HSC) activation, and collagen deposition.9 Similarly,
other studies using both pharmacological and genetic CTSB
inactivation observed reduced hepatic inflammation, as
assessed by transcripts for CXC-chemokines and neutrophil
infiltration after cholestasis.19 However, in both studies, the
mechanism behind the pro-inflammatory role of CTSB was
lacking.
Given the central role of NF-κB in hepatic inflammation and
the recognized participation of SIRT1 in liver homeostasis, we
wondered if there exists a connection between SIRT1 and
NF-κB in hepatic inflammation, and if cysteine cathepsins
were somehow modulating this outcome. To this aim, we
analyzed in different liver cell types if physiological effectors of
hepatic damage and inflammation, such as TNF or LPS,
through NF-κB, were affected by cysteine cathepsin inhibition,
and if SIRT1 was involved in this process.
Results
In HSCs NF-κB-dependent gene-expression is modulated
by SIRT1 through CTSB/S. To evaluate the role of cysteine
cathepsins in NF-κB-dependent inflammatory gene expres-
sion, mouse primary activated HSCs (8-days) were chal-
lenged with LPS or TNF. Both mediators induced an
enhancement of the κB-dependent MCP1 chemokine, and
IL6 cytokine mRNAs. Preincubation of HSCs with CA-074-
methyl-ester or Z-FL-COCHO, CTSB and CTSS inhibitors,
respectively,20,21 greatly reduced TNF- or LPS-induced
MCP1 and IL6 mRNA (Figure 1a). Consistent with this, in
activated primary HSCs, p65-NF-κB nuclear translocation
upon TNF challenge was reduced in cells after CTSB
inhibition (Figure 1b). In addition, CTSB, as expected,9 and
also CTSS increased their expression during the HSC
activation process. Of note, in primary HSCs, SIRT1’s
gradual increase during activation was suppressed in fully
activated HSCs (Figure 1c), coinciding with the maximum
cathepsin expression. In fact, SIRT1 levels increased after
CTSB or CTSS inhibition (Figure 1d), thus supporting the
cleavage of SIRT1 by cysteine cathepsins in HSCs, as
described previously in other cell types.17,18 Of interest, in the
human HSC cell line LX2,22 LPS or TNF administration
resulted in p65-NF-κB and p50-NF-κB, nuclear translocation
that was blunted upon preincubation with CTSB or CTSS
inhibitors (Figure 2a). Confocal microscopy also revealed that
p65-NF-κB nuclear presence was reduced by Cathepsin
B or S (CTSB/S) inhibition after TNF challenge (Figure 2b).
Moreover, CTSB inhibition reduced overall p65-NF-κB
nuclear presence, induced by TNF, at all time-points analyzed
(Figure 2c). In addition, CTSB or CTSS inhibitors, by
themselves, did not alter MCP1 or IL6 expression, or induced
p65-p50-NF-κB translocation, as compared to untreated
HSCs or LX2 cells (not shown); however they were able to
greatly diminish the enhanced MCP1 and IL6 mRNA
expression induced by TNF or LPS (Figure 2d).
To determine if SIRT1 expression could modulate the
NF-κB-dependent response, LX2 cells were preincubated
Figure 1 Cysteine cathepsins modulate SIRT1 and NF-κB induction in primary
HSCs. (a) MCP1 and IL6 mRNA expression in primary HSCs (8-days) preincubated
with CA-074 (25 μM) or Z-FL (10 μM) overnight, and exposed to TNF (50 ng/ml) or
LPS (50 ng/ml) for 6 h. (b) Immunoblots displaying nuclear extracts of HSCs (8-days)
treated with CA-074, overnight, and challenged with TNF for 10 min. (c) α-SMA,
SIRT1, CTSB, and CTSS protein expression during primary HSC transdifferentiation.
(d) Expression of SIRT1 in HSCs (8-days) exposed to CA-074 or Z-FL, overnight.
Results are given as mean± S.D., n= 8; *Po0.001 versus Control, and ¶Po0.001
versus LPS or TNF treatment
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with SIRT1 activator (Resveratrol, RSV) or inhibitor (Tenovin-
6, Ten6), and exposed to LPS. As shown in Figure 2e,
LPS-induced MCP1 mRNA expression was diminished upon
SIRT1 activation and enhanced after its antagonism. Similarly,
in LX2 cells infected with SIRT1 shRNA, stable SIRT1
decrease (~90% SIRT1 mRNA decline) led to superior
MCP1 and IL6 mRNA expression (Figure 2f) upon
TNF exposure, as compared to control shRNA-infected
LX2 cells. Of note, while CTSB or CTSS inhibition in control
shRNA LX2 cells induced a decrease in MCP1 and IL6 mRNA
expression, versus TNF only, this outcome was not observed
in SIRT1 shRNA clones (Figure 2f), therefore implicating that
SIRT1’s presence is required for cathepsins to affect
NF-κB-dependent transcription.
Figure 2 Regulation of NF-κB-dependent gene expression by CTSB and CTSS in LX2 cells. (a) Immunoblot of nuclear extracts, or (b) p65-NF-κB confocal microscopy of LX2
cells exposed to CA-074 (25 μM) or Z-FL (10 μM) overnight, and challenged for 10 min TNF (50 ng/ml), or after 30 min LPS (50 ng/ml). (c) Time course of p65-NF-κB in nuclear
extracts of LX2 cells exposed to TNF with/without preincubation with CA-074 (25 μM, overnight). (d) mRNA expression of MCP1 and IL6 in LX2 cells after overnight preincubation
with CA-074 or Z-FL followed by exposure to TNF or LPS for 6 h. (e) MCP1 mRNA expression in LX2 cells preincubated overnight with Ten6 (10 μM) or RSV (100 μM) followed by
6 h LPS. (f) MCP1 and IL6 mRNA expression in LX2 cells infected with Control or SIRT1 shRNA, preincubated with CA-074 (25 μM) or Z-FL (10 μM) followed by exposure to 6 h
TNF. Results are given as mean± S.D., n= 4; *Po0.05 versus control or shControl, and ¶Po0.05 versus LPS- or TNF-treated cells
Cysteine cathepsins control NF-κB-dependent inﬂammation
Á de Mingo et al
3
Cell Death and Disease
NF-κB-dependent gene expression is modulated by
CTSB/S in hepatocytes. We next evaluated whether a
similar relationship was present in hepatocytes. Primary
mouse hepatocytes were treated with TNF, and p65 nuclear
translocation and the expression of the NF-κB-dependent
antiapoptotic protein A20 were analyzed. TNF-induced
translocation of p65-NF-κB to the nucleus was decreased
upon CTSB or CTSS inhibition, accompanied by an increase
in nuclear SIRT1 expression (Figure 3a). Moreover, p65
translocation correlated with NF-κB-dependent expression of
A20 mRNA (Figure 3b).
We also evaluated in Hep3B cells, a human hepatoma cell
line, mRNA expression of A20 and of IL8, a chemokine
induced by TNF in human cell types with no murine homolog.
In Hep3B cells, TNF-induced A20 and IL8 mRNA expression
levels were greatly reduced after CTSB or CTSS inhibition
(Figure 3c). Moreover, in LX2 cells treated with LPS, TNF, or
chloroquine (a lysosomotropic agent, used as a positive
control) we observed the release of CTSB to the cytosol in
LX2, but only after TNF challenge in Hep3B, consistent with
their low TLR4 activity (Figure 3d).
In macrophages, NF-κB-dependent inflammatory
response is controlled by CTSB/S. We next moved to
primary Kupffer cells (KCs), since LPS-mediated KC activa-
tion is a key mechanism in the pathogenesis of various liver
diseases.1 In KCs, LPS exposure induced p65-NF-κB nuclear
translocation accompanied by a prominent MCP1 and IL6
mRNA induction that was blunted after CTSB or CTSS
inhibition (Figures 4a and b). We next corroborated our
observations in RAW264.7, murine macrophage cells,
observing parallel results (Figures 4c and d). Both in KCs
and RAW264.7 cells, the concentration of CTSB inhibitor was
increased to 75 μM in order to achieve optimal CTSB
inhibition (490%). CTSS inhibition in RAW264.7 cells
resulted in cell death; therefore it was not used for this set
of experiments. Of interest, in RAW264.7 cells, LPS induced
a decrease in SIRT1-110 kDa that was recovered after CTSB
inhibition (Figure 4c). This result was corroborated by
measuring SIRT1 activity (Figure 4e). Of note, it is interesting
to observe that while CTSB inhibition per se did not affect
either p65-NF-κB translocation, or MCP1 and IL6 mRNA
expression (not shown), it did enhance SIRT1 activity in
RAW264.7 cells independent of LPS treatment (Figure 4e).
The processing of SIRT1 correlated with CTSB activity
and the inflammatory phenotype. In RAW264.7 cells, the
SIRT1 immunoblot, apart from the full-length 110 kDa band,
resolved two additional bands (75 and 35 kDa), bands that
were barely visible in LX2 or Hep3B cells where the full-
length protein, SIRT1-110 kDa, was most noticeable
(Figure 5a). Consistent with this, in the nucleus, the active
isoform of SIRT1 was present in LX2 and Hep3B cells but
almost inexistent in RAW264.7 cells, where we only observed
the SIRT1-75 kDa form (Figure 5b). On the other hand, when
measuring CTSB activity in the different cells, we observe
remarkable variations among cells. Interestingly, macro-
phages, both RAW264.7 cells and KCs, exhibit more CTSB
activity (eight- and threefold, as compared to LX2 and HSCs
respectively) than the other cell types. In contrast, CTSS
activity was more stable between the three cell populations,
displaying no consistent differences between phenotypes
(Figures 5c and d). Therefore, as RAW264.7 cells display an
inflammatory phenotype and higher levels of CTSB, we
chose this cell line for analyzing SIRT1 and CTSB location by
confocal microscopy. CTSB inhibition increased nuclear
SIRT1 in LPS-treated cells (in green) (Figure 5e). In addition,
Figure 3 Effect of CTSB/S inhibition on NF-κB activation in hepatocytes. Primary
mouse hepatocytes were exposed to CA-074 (25 μM) or Z-FL (10 μM), overnight or
for 4 h. (a) Nuclear protein levels were analyzed after 10 min TNF challenge. (b) A20
mRNA expression was quantified after 6 h TNF challenge. (c) A20 and IL8 mRNA
expression in Hep3B cells pre-treated overnight with CA-074 (25 μM) or Z-FL
(10 μM) before 6 h TNF challenge. (d) Immunoblot of CTSB in the cytosolic fraction
after challenging LX2 or Hep3B cells with LPS, TNF or chloroquine (CQ, 50 μM) for
60 min. Results are given as mean± S.D., n= 5; *Po0.001 versus control, and
¶Po0.001 versus TNF
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it is important to stress that the CTSB inhibitor is inhibiting
CTSB activity, but not removing CTSB protein. That is why,
although inactive, CTSB levels appear increased after its
inhibition. These results, together with the observation that in
RAW264.7 cells, CTSB inhibition enhances SIRT1 activity
(Figure 4e), suggest that the processing of SIRT1 correlates
with CTSB activity, in the different cell lines analyzed, and
with their potential inflammatory phenotype.
In vivo, CTSB/S inhibition lessens LPS-derived
NF-κB-dependent inflammatory gene expression. To vali-
date our observations in vitro, we next moved onto in vivo
studies. First, we induced acute inflammation in healthy mice
with LPS for 6 h. Neither CA-074 nor Z-FL by themselves,
administered 1 h prior LPS, had any effect on liver damage or
basal κB-dependent gene expression and behaved like the
untreated control mice (not shown). NF-κB-dependent genes
increased upon LPS challenge, and this induction was
diminished in mice after CTSB or CTSS inhibition
(Figure 6a). Treatment of mice with liposomal clodronate
significantly reduced the extent of MCP1 and IL6 mRNA
induction, indicating KCs as its source (Fig. S1). Of interest,
LPS-induced liver damage was significantly reduced
in mice receiving CTSB inhibitor, but not after CTSS
inhibition (Figure 6b), suggesting, in addition to lessening
inflammation, a specific role of CSTB in LPS-dependent
hepatocyte cell death. Of note, both inhibitors did increase,
per se and after LPS injection, total hepatic SIRT1 activity
(Figure 6c).
Next, we evaluated CTSB/S inhibition in animals with liver
fibrosis, where an important inflammatory response to LPS
was expected. The experimental setup, H&E and Sirius Red
staining of hepatic specimens are displayed in Figure 7a. As
shown in Figure 7b, LPS-induced MCP1 and IL6 mRNA
expression wasmuch greater than in healthy mice (Figure 6a).
Importantly, CTSB and CTSS inhibition significantly reduced
LPS-dependent MCP1 and IL6 mRNA expression, thus
confirming the effectiveness of this strategy in controlling
hepatic inflammation. Again, CTSB/S inhibition resulted in a
significant increase in hepatic SIRT1 activity (Figure 7c) even
in LPS-treated mice, thus suggesting that enhanced SIRT1
activity results in decreased NF-κB-dependent induction of
inflammatory gene expression.
CTSB inhibition reduced inflammation in a murine model
of non-alcoholic steatohepatitis (NASH). We next
assessed in a dietary model of NASH (a high-fat choline-
deficient (HFCD) diet) that causes macrovesicular steatosis,
fibrosis, and inflammation23 the effect of CTSB inhibition. The
experimental setup is described in Figure 8a. HFCD-feeding
induced CTSB activation as observed by the processing of
pro-CTSB in liver samples, and reduced full-length SIRT1
(Figure 8b). CTSB inhibition partly recovered pro-CTSB and
SIRT1 levels (Figure 8b) but did not alter liver damage
(Figure 8c). We also observed enhanced activation of
caspase-1 in HFCD-fed mice, indicative of NLRP3-
inflammasome activation, which was not altered by CTSB
inhibition. H&E and Sirius Red staining are shown in
Figure 8d. As expected, HFCD induced hepatic inflammation
and fibrosis. The improvement in the collagen deposit
observed after CTSB inhibition did not reach statistical
significance (P=0.14, n=6) at the time point analyzed.
However, a gene array revealed that HFCD induced
important alterations in the expression of genes related to
fibrosis and inflammation (i.e. FasL, IFNγ, MMPs, LOX, TNF,
chemokines, TIMP1), many of them NF-κB-dependent, that
significantly improved after CTSB inhibition (Figure 8e).
Figure 4 NF-κB-dependent response to LPS is controlled by cathepsins in macrophages. KCs were exposed overnight to CA-074 (75 μM) or Z-FL (7.5 μM) and (a) nuclear
proteins were analyzed after LPS (50 ng/ml, 30 min) challenge, or (b) IL6 and MCP1 mRNA expression was analyzed after 6 h LPS. RAW264.7 cells were pre-treated with
CA-074 (75 μM, 4 h) and (c) nuclear proteins analyzed after LPS challenge (50 ng/ml, 30 min), or (d) MCP1 and IL6 mRNA expression was analyzed after 6 h LPS. (e) Total
SIRT1 activity was determined in RAW264.7 cells pre-treated with CA-074 (75 μM, overnight) and exposed to LPS (30 min). Results are given as mean± S.D., n= 4; *Po0.001
versus Control, and ¶Po0.05 versus LPS
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Discussion
Cathepsins are proteolytic enzymes implicated in awide range
of physiological functions, including cytosolic and nuclear
functionality as revealed by several studies.12,24 TNF could
also destabilize lysosomal membranes, thus releasing cathe-
psins to the cytosol,25 as we observed in LX2 and Hep3B cells
(Figure 3d). p65-NF-κB subunit is acetylated in the nucleus,
which is essential to maintain its nuclear localization and
consequent NF-κB transcriptional activity,26,27 and it can be
Figure 5 SIRT1 correlates with CTSB activity in cell lines and primary cells. (a)
Total and (b) nuclear SIRT1 expression; and (c) CTSB and CTSS activities in LX2,
Hep3B and RAW264.7 cells. (d) CTSB and CTSS activity in HSCs (8-days old),
hepatocytes, and KCs. (e) SIRT1 and CTSB confocal microscopy of RAW264.7
macrophages pretreated with CA-074 (75 μM, 4 h) before LPS challenge (50 ng/ml,
30 min). Representative image, n= 3. Results are given as a mean± S.D., n= 5;
*Po0.001 compared to LX2 or HSCs values
Figure 6 Effect of CTSB/S inhibition in an in vivo model of acute inflammation.
Mice were treated with CTSB/S inhibitors (10 mg/kg) 1 h before LPS i.p. injection
(1.0 mg/kg, 6 h) and (a) MCP1 and IL6 mRNA expression was determined in liver
tissue, (b) ALT levels were measured in blood collected at 0, 4, 6 h, and (c) hepatic
SIRT1 activity was analyzed. Results are given as a mean±S.E.M., n= 6,
*Po0.001 versus Control, and ¶Po0.05 versus LPS
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deacetylated by SIRT1 decreasing NF-κB-dependent gene
expression.8,28 In activated HSCs, SIRT1 expression is
inversely controlled by CTSB and CTSS activities, SIRT1
lowering being essential to establish the pro-inflammatory
phenotype of activated HSCs. Our data in activated HSCs
confirm the recovery of SIRT1-110 kDa after CTSB/S inhibi-
tion (Figure 1d), underscoring the role of SIRT1-CTSB/S axis
in HSC activation. Of note, CTSB inhibition significantly
reduces the overall presence of p65-NF-κB in the nuclear
fraction after TNF challenge in LX2 cells, thus suggesting that
SIRT1 upregulation contributes not only to end transcription
but also to diminish p65-NF-κB nuclear presence. Given that
SIRT1 deacetylation of p65 has been mainly associated with
the ending of NF-κB transcription, the observation that it can
also regulate p65 nuclear export merits further investigation.8
SIRT1 inhibitor (Tenovin-6) and activator (Resveratrol) have
opposite effects as modulators of SIRT1 activity. In our study,
we observe that inflammation is enhanced when SIRT1 is
inactivated by Tenovin-6, whereas cells are protected against
inflammation by the use of Resveratrol (Figure 2e). These
results corroborate that SIRT1 is tightly implicated in the
regulation of κB-dependent gene expression. To better
analyze the participation of cysteine cathepsins in this
process, we transfected human LX2 cells with lentiviral
particles shSIRT1 and shControl. As we expected, the
shSIRT1-LX2 cell line expressed a higher inflammatory
phenotype compared to the shControl LX2 cells. Of interest,
the employment of CTSB/S inhibitors in the shSIRT1-LX2
clone did not alter κB-dependent gene expression after TNF
challenge, which pointed out that in the absence of SIRT1, the
inhibition of CTSB or CTSS was ineffective, therefore
reinforcing the direct link between SIRT1 and cathepsins. In
sum, our data indicate that cathepsin/SIRT1 modulation
controls NF-κB-dependent gene expression in activated
HSCs, providing a novel targetable pathway to induce
phenotypic changes in HSCs during liver pathology.
On the macrophage side, the expansion of our observations
to KCs and RAW264.7 cells, which have a prominent
inflammatory phenotype, allowed us to corroborate CTSB/S
inhibition as an effective strategy to control κB-dependent
gene expression, under conditionswhere amassive release of
cytokines and chemokines is induced. Interestingly, when we
analyzed the expression of CTSB/S and SIRT1, we observed
that RAW264.7 cells showed the highest CTSB activity, which
was followed by virtually no presence of active SIRT1-
110 kDa, presenting the truncated forms, SIRT1-75 kDa and
SIRT1-35 kDa. In contrast, other liver cell types, such as LX2
and Hep3B cells, have predominantly the SIRT1-110 kDa full
length form. More importantly, CTSB inhibition per se promi-
nently recovered SIRT1 activity, by increasing it by 4-5-fold,
thus emphasizing the relationship between these enzymes in
macrophages. In KCs and in RAW264.7 cells higher doses of
the CTSB inhibitor (75 μM instead of 25 μM) were required to
achieve optimal CTSB inhibition (490%), probably reflecting
the high presence of this protease in macrophages. In
addition, SIRT1 activity studies also revealed that upon LPS
challenge there was a significant decrease in SIRT1 protein
and activity in RAW264.7 cells, which could be related to the
leakage of CTSB from lysosomes observed after this stimulus,
suggesting that some lysosomal membrane permeabilization
(LMP) may be taking place.
Finally, we tried to translate our in vitro observations to
in vivo models of acute hepatic inflammation in healthy and
fibrotic mice by LPS injection. In these settings, NF-κB-
Figure 7 Effect of CTSB/S inhibition on liver inflammation in mice with hepatic
fibrosis. (a) After inducing liver fibrosis in mice by CCl4 injection (twice weekly, 0.5 μl/
gr) and after H&E and Sirius Red staining displaying collagen accumulation, mice
received CTSB/S inhibitors (10 mg/kg) followed 1 h later by LPS i.p. injection (1.0 mg/
kg, 6 h). Then, (b) MCP1 and IL6 mRNA expression was determined in liver tissue,
and (c) hepatic SIRT1 activity was analyzed. (a) Results are given as a mean± S.E.
M., n= 6, *Po0.001 versus Control, ¶Po0.001 versus LPS, and (b) **Po0.05
versus Ctrl with CCl4
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Figure 8 CTSB inhibition reduces inflammatory gene expression in mice with NASH. NASH was induced by feeding mice a HFCD diet for 8 weeks, CA-074-treated mice
received a daily dose (10 mg/kg) for the last week. (a) Experimental setup, (b) CTSB, SIRT1 and active Caspase-1 immunoblot of hepatic lysates, (c) transaminases in serum, (d)
H&E and Sirius Red staining. Results are given as mean±S.E.M., n= 6, *Po0.01 versus Control. (e) Gene array of Control, HFCD, and HFCD+CA-074 mice displaying only
those genes altered in the HFCD group that significantly improved after CA-074 treatment. For complete gene array, please refer to Figure S2
Cysteine cathepsins control NF-κB-dependent inﬂammation
Á de Mingo et al
8
Cell Death and Disease
dependent genes increased upon LPS challenge and
decreased after CTSB/S inhibition, while SIRT1 activity did
the opposite, hence reproducing our in vitro results in a more
complex setup. In addition, transaminase levels indicate that
CTSB inhibition, but not CTSS inhibition, lessened liver
damage after LPS challenge, which could indicate again the
participation of this protease in apoptotic pathways and LMP
induced by TNF/LPS in hepatocytes, as described by
others.13,14 Of note, several groups, ours among others,9
have observed that antagonism of CTSB, either genetic or
pharmacological, results in reduced inflammation and/or
hepatic fibrosis.9,19,29–31 In these studies, the reduced
inflammation observed was considered secondary to the
general improvement in hepatic condition mainly attributed to
CTSB’s role in hepatocyte apoptosis,15,19,29,31 or, in fibrogen-
esis, as a regulator of the PI3K/AKT pathway in response to
PDGF in HSCs.9 However, our study provides direct evidence
of the mechanism behind CTSB’s pro-inflammatory role, as a
modulator of the NF-κB-inflammatory response, through
SIRT1, in macrophages, HSCs, and probably in other
inflammatory cells infiltrating the liver. Interestingly, we tried
to attain the same goal by administering the SIRT1 agonist
SRT2104 (100 mg/kg, 1 week) to mice in our CCl4-induced
liver fibrosis model, without achieving recovery in SIRT1
activity (data not shown), and, accordingly, liver inflammation
or damage was not modified by SRT2104 treatment. In
contrast, the consistent increase in SIRT1 activity, both after
LPS challenge in control and CCl4-exposed mice, and in the
NASHmurine model, obtained by CTSB inhibition, revealed to
be a highly effective strategy to recover SIRT1 levels in the
damaged liver.
Related to the role of CTSB/SIRT1 in NASH, our previous
studies showed in patients with NASH, compared with healthy
controls, that CTSB mRNA was increased eightfold, suggest-
ing CTSB participation in disease progression.32 Additionally,
hepatic SIRT1 expression is reduced not only in different
animal models of NAFLD33 but also in patients with NASH
correlating with disease severity.34 Of relevance, deletion of
SIRT1 in mice fed a high-fat diet results in hepatic steatosis
and inflammation.6 In our NASH model, significant changes in
gene expression and overall improvement in many genes
related to inflammation (FasL, IFNg, TNF, chemokines) and
fibrosis (TIMP1, LOX, Col3a1, MMPs, TGFBR) is observed
after CTSB inhibition in HFCD-fed mice, in parallel with
increased SIRT1 expression.
Of interest, the participation of CTSB in the activation of the
NLRP3 inflammasome is still debated,35 which contributes to
enhance the inflammatory state in NASH by activating
Caspase-1 and inducing the release of IL-1β. In this aspect,
and despite CTSB being activated upon HFCD feeding, we
observe enhanced Caspase-1 activation that was not affected
by CTSB inhibition, not supporting a prominent role for CTSB
in inflammasome activation in this setting.
Overall, our study discloses the CTSB/S-SIRT1 axis as a
new route for controlling inflammation in acute and chronic
hepatic diseases. In fact, given the presence of this control
pathway in all hepatic cells analyzed and in RAW264.7 cells, it
is possible that the importance of this mechanism reaches
beyond the liver. Our data demonstrate that cysteine
cathepsin inhibition limits NF-κB-dependent hepatic
inflammation through the regulation of SIRT1, and conse-
quently provides an anti-inflammatory targetable pathway in
liver therapy, and possibly in other organs.
Materials and Methods
Cell lines and cell treatment. Commercially available Hep3B, RAW264.7
cells (ECACC, Sigma-Aldrich, St. Louis, MO, USA) were used. LX2 cells were kindly
given by Dr. Ramón Bataller (IDIBAPS, Barcelona, Spain). All cell lines are
mycoplasma-free. Human recombinant TNF (Peprotech, Rocky Hill, NJ, USA), LPS
(E. coli 0111:B4, Sigma-Aldrich) were administered to cells at 50 ng/ml. CTSB
inhibitor (CA-074 methyl ester, Sigma-Aldrich) was given at 25 μM to primary
hepatocytes, HSCs, Hep3B and LX2 cells and at 75 μM to KCs and RAW264.7
cells. CTSS inhibitor (Z-FL-COCHO, Calbiochem, San Diego, CA, USA) was given
at 10 μM to primary hepatocytes, HSCs, Hep3B and LX2 cells and at 7.5 μM to
KCs. Resveratrol (100 μM) and Tenovin-6 (10 μM) (Santa Cruz Biotechnology,
Dallas, TX, USA) were given to LX2 cells. Control and human SIRT1 shRNA
lentiviral particles commercially available were used (Santa Cruz Biotechnology).
In vivo models. Animal studies were conducted in accordance with the
principles and procedures outlined in the National Institutes of Health Guide for the
Care and Use of Laboratory Animals and were approved by the institutional animal
care committee of the Universitat de Barcelona. Animals were monitored daily and
those with evident discomfort were euthanized, according to approved protocol.
C57BL/6 male mice, 8–10 weeks old, were used. In all groups (n= 6), animals were
randomly assigned to the different groups and the liver specimens and samples
obtained were blindly analyzed. Liver fibrosis was induced by injecting CCl4 (5 μl/g
of a 10% solution of CCl4 in corn oil) twice-weekly, for 4 weeks. Acute inflammation
was induced in healthy mice by a single LPS injection (1.0 mg/kg, intraperitoneal).
Treatment with CA-074-Me or Z-FL inhibitors (10 mg/kg, intraperitoneal) was
initiated 1 h before LPS. In mice with fibrosis LPS was given 72 h after the last dose
of CCl4. Mice were killed6 h after LPS. Control animals received vehicle alone. To
induce NASH, mice were fed a HFCD (60% kcal) diet with 0.1% methionine (Open
Source diets #A06071302) for 8 weeks, receiving daily doses of CA-074-Me
(10 mg/kg, intraperitoneal) for the last week.
Isolation and culture of hepatic parenquimal and non-
parenquimal cells (NPCs). C57BL/6 male mice, 8–12 weeks old, were
from Charles River (Wilmington, MA, USA). Hepatocytes, HSCs and KCs were
isolated by liver perfusion with collagenase-pronase as described9 with small
modifications. Hepatocytes were separated from NPCs by 60 g centrifugation. The
supernatant containing NPCs was collected and centrifuged at 600 g for 8 min. The
NPC pellet was resuspended in 6 ml of GBSS and mixed with 6 ml of cold
Nycodenz at 32% to reach 16%, then it was topped with 2 ml GBSS and centrifuged
at 2300 g, 45 min, 4 °C without break. KCs appear in the interface and HSCs in the
brown cloudy strip. NPCs were collected with a Pasteur tip, washed twice with
GBSS at 500 g, 5 min, 4 °C and resuspended in culture media. Hepatocytes and
HSCs were cultured in DMEM, and KCs in RPMI, both media complemented with
10% FBS, and antibiotics at 37°C in a humidified atmosphere of 95% air and 5%
CO2.
KCs elimination by clodronate injection. Commercially available
suspension of liposome-encapsulated clodronate containing 5 mg of clodronate
per 1 ml or vehicle (PBS) (www.clodronateliposomes.com) was given to mice by i.p.
injection (dose 0.1 ml/10g mouse) 48 h before LPS.
SDS-PAGE and immunoblot analysis. Cell lysates were prepared in
RIPA buffer (50 mM Tris·HCl, pH 8, 150 mM NaCl, 1% Nonidet P-40, 0.1% SDS, 1%
Triton X-100 plus proteinase inhibitors). Protein concentration was determined by
Bradford assay, and samples containing 10–50 μg were separated by SDS-PAGE.
Proteins were transferred to nitrocellulose membranes. After this, membranes were
blocked in 8% nonfat milk in 20 mM Tris-HCl, 150 mM NaCl, and 0.05% Tween-20
for 1 h at room temperature.
Antibodies. Anti-SIRT1 (sc-15404), anti-CTSS (sc-6505), anti-p65-NFκB (sc-
372), anti-p50-NFκB (sc-7178), anti-Lamin (sc-6215) were taken from Santa Cruz
Biotechnology; anti-β-actin-HRP (A3854) from Sigma-Aldrich; anti-alpha smooth
muscle actin (A5228) from Sigma; and anti-CTSB (06-480) from Millipore (Billerica,
MA, USA).
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CTSB, CTSS and SIRT1 activities. CTSB activity was assayed fluori-
metrically with Z-Arg-Arg-7-amido-4-methylcoumarin hydrochloride (60 μmol/L) at
pH 7.4 and 37 °C as previously described.9 CTSS and SIRT1 activities were
determined fluorimetrically using commercially available kits (ab65307 and
ab156065 respectively, Abcam, Cambridge, UK) and following the manufacturer’s
instructions.
Nuclear extract isolation. 2 × 106 cells were scraped in Buffer A (10 mmol/L
Hepes, 10 mmol/L KCl, 0.1 mmol/L ethylenediaminetetraacetic acid (EDTA),
0.1 mmol/L ethylene glycol tetraacetic acid (EGTA), 1 mmol/l dithiothreitol (DTT),
and 0.5 mmol/l phenylmethylsulfonyl fluoride (PMSF), kept on ice for 15 min, lysed
by the addition of 1/20 (vol/vol) 10% Igepal and vortexed for 10 s. Nuclei were
pelleted (12 000 g, 30 s), resuspended in Buffer C (20 mmol/lHepes, 0.4 mol/l NaCl,
1 mmol/l EDTA, 1 mmol/l EGTA, 1 mmol/l DTT, and 1 mmol/l PMSF), and incubated
for 15 min on ice with gentle mixing. Subsequently, nuclear extracts were obtained
by centrifuging at 4 ºC, 12 000 g for 5 min.
H&E and sirius red staining. Livers were formalin-fixed and 7 μm sections
were routinely stained with H&E or a 0.1% Sirius Red-picric solution following
standard procedures. The slices were examined with a Zeiss Axioplan microscope
equipped with a Nikon DXM1200F digital camera. For collagen-fiber determination
series of four random selected fields from each slice were visualized and quantified
using Quantity One software (Bio-Rad Laboratories, Hercules, CA, USA).
shRNA lentiviral infection. Infection with control or hSIRT1 shRNA
Lentiviral particles was performed following the manufacturer’s protocol (Santa
Cruz Biotechnology). Briefly, LX2 cells were grown in a 12-well plate to 50%
confluency and infected with 10 μl of lentiviral particles in the presence of 5 μg/ml
Polybrene. Forty-eight hours after infection, selection of clones was performed in
complete media containing Puromycin (2 μg/ml) until resistant colonies can be
identified and selected.
Laser confocal imaging. Cells were cultured on coverslips for different time-
points. A 4% paraformaldehyde solution was used as a fixative agent for 15 min.
When necessary cells were permeabilized with 0.1% saponine/0.5% BSA fatty acid
free/PBS 1 × for 15 min, and blocked for 45 min in 3% BSA/PBS buffer. Coverslips
were incubated overnight with the primary antibodies in 1% BSA/PBS buffer.
Afterwards they were rinsed with PBS buffer and incubated with fluorescent
secondary antibodies for 45 min. After final washes in PBS, coverslips incubated
with either DAPI or DRAQ5 for 30 min in the dark to stain the nuclei and next were
washed with PBS and mounted in Fluorescent Mounting Medium. Confocal images
were collected using a laser scanning confocal microscope Leica DM 2500.
RNA isolation and Real-Time RT-PCR. Total RNA was isolated with
TRIzol reagent. Real-time RT-PCR was performed with iScript One-Step reverse
transcription (RT)-PCR Kit with SYBR Green following the manufacturer's
instructions (Bio-Rad Laboratories). The primers sequences used are described
in Table 1.
Gene array. A predesigned 384-well mouse fibrosis panel for use with SYBR
Green (Bio-rad) was used following the manufacturer’s instructions. Briefly, after
isolating RNA with the TRIzol reagent, the corresponding cDNA was synthesized
using the iScript advanced cDNA synthesis kit (Bio-rad). Once cDNA is obtained the
PCR reaction mix is prepared (SsoAdvanced universal SYBR Green supermix) and
added to the 384-well plate where all the primers are lyophilized. Results are
corrected and normalized to the housekeeping genes β-actin and Tbp.
Statistical analysis. All in vitro experiments were repeated at least three
times. Results are expressed as mean± S.D for cell studies, and as mean±S.E.M.
for in vivo studies. Statistical comparisons were performed using unpaired two-tailed
Student’s t test, since the samples have similar variance. All analyses were
performed using GraphPad Prism. A P valueo0.05 was considered significant.
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